title: International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005.
abstract: The International Circumpolar Surveillance System is a population-based surveillance network for invasive bacterial disease in the Arctic. The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced for routine infant vaccination in Alaska (2001), northern Canada (2002-2006), and Norway (2006). Data for invasive pneumococcal disease (IPD) were analyzed to identify clinical findings, disease rates, serotype distribution, and antimicrobial drug susceptibility; 11,244 IPD cases were reported. Pneumonia and bacteremia were common clinical findings. Rates of IPD among indigenous persons in Alaska and northern Canada were 43 and 38 cases per 100,000 population, respectively. Rates in children <2 years of age ranged from 21 to 153 cases per 100,000 population. In Alaska and northern Canada, IPD rates in children <2 years of age caused by PCV7 serotypes decreased by >80% after routine vaccination. IPD rates are high among indigenous persons and children in Arctic countries. After vaccine introduction, IPD caused by non-PCV7 serotypes increased in Alaska.
authors.affiliation: Arctic Investigations Program, National Center for Preparedness, Detection, and Control of Infectious Diseases, Centers for Disease Control and Prevention, 4055 Tudor Circle Drive, Anchorage, AK 99508, USA. zwa8@cdc.gov
authors.forename: Michael G
authors.initials: MG
authors.lastname: Bruce
authors.forename: Shelley L
authors.initials: SL
authors.lastname: Deeks
authors.forename: Tammy
authors.initials: T
authors.lastname: Zulz
authors.forename: Dana
authors.initials: D
authors.lastname: Bruden
authors.forename: Christine
authors.initials: C
authors.lastname: Navarro
authors.forename: Marguerite
authors.initials: M
authors.lastname: Lovgren
authors.forename: Louise
authors.initials: L
authors.lastname: Jette
authors.forename: Karl
authors.initials: K
authors.lastname: Kristinsson
authors.forename: Gudrun
authors.initials: G
authors.lastname: Sigmundsdottir
authors.forename: Knud Brinkløv
authors.initials: KB
authors.lastname: Jensen
authors.forename: Oistein
authors.initials: O
authors.lastname: Lovoll
authors.forename: J Pekka
authors.initials: JP
authors.lastname: Nuorti
authors.forename: Elja
authors.initials: E
authors.lastname: Herva
authors.forename: Anders
authors.initials: A
authors.lastname: Nystedt
authors.forename: Anders
authors.initials: A
authors.lastname: Sjostedt
authors.forename: Anders
authors.initials: A
authors.lastname: Koch
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Hennessy
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Parkinson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001110:Arctic Regions / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003081:Cold Climate; D003140:Communicable Disease Control / Q000379:methods; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology*; D022242:Pneumococcal Vaccines / Q000627:therapeutic use; D044382:Population Groups; D011159:Population Surveillance; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects / Q000276:immunology
chemical_list: D022242:Pneumococcal Vaccines